ライブ
ScienceDeepfakes are everywhere. The godfather of digital forensics is fighting backEndpoints NewsFDA's oncology advisors vote against 'new paradigm' in AstraZeneca trialEndpoints NewsKrazati fails confirmatory trial in colorectal cancer, putting approval at risk10x Genomics BlogWhy 10x Genomics Stock Is Surging Today - TipRanksFierceBiotechAstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposalEndpoints NewsHouse panel calls to ban China trial data from FDA drug trial applicationsEndpoints NewsCourt dismisses part of Lilly lawsuit against Empower, some claims can proceedEndpoints NewsSupreme Court questions how far generics makers can go with 'skinny label' drugsIlluminaTempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now? - TradingViewMACHEREY-NAGEL GmbH & Co. KGWorld Laboratory Filter Paper - Market Analysis, Forecast, Size, Trends and Insights - IndexBoxMerck KGaAMerck KGaA taps into Remepy’s Hybrid Drug platform - The Pharma LetterGE HealthCareGE HealthCare’s stock plunges 13% as supply chain costs bite - Medical Device Network
BioPharma Dive 2026年4月30日

Merck still sees ‘compelling’ outlook for Terns leukemia drug

Merck still sees ‘compelling’ outlook for Terns leukemia drug

原文
本文は利用できません。元の情報源をご確認ください。